Related Experiment Videos
Embryonal malignancies of unknown primary origin in children
J F Kuttesch1, D M Parham, S C Kaste
1Department of Hematology-Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee.
Cancer
|January 1, 1995
Summary
Pediatric embryonal malignancies of unknown primary origin are rare. An exhaustive search for the primary site is not recommended; focus on accurate diagnosis and tailored therapy for potential long-term survival.
Area of Science:
- Pediatric Oncology
- Pediatric Pathology
- Pediatric Cancer Research
Background:
- Embryonal malignancies of unknown primary origin in children are poorly understood.
- A 30-year review of cases at a pediatric cancer center was conducted.
- The study aimed to define clinical and prognostic features and guide evaluation and therapy.
Purpose of the Study:
- To characterize embryonal malignancies of unknown primary origin in pediatric patients.
- To identify key diagnostic tools and prognostic factors.
- To develop recommendations for the management of these rare cancers.
Main Methods:
- Retrospective review of 17 pediatric patients with embryonal malignancies of unknown primary origin.
- Analysis of medical records, imaging, laboratory data, and pathology reports.
- Pathology review to confirm or revise initial diagnoses.
Main Results:
- Histologic diagnoses included rhabdomyosarcoma (9), neuroblastoma (7), and Ewing's sarcoma (1).
- Extensive imaging revealed abnormalities in most patients; bone marrow sampling and urinary catecholamines were valuable.
- Primary site identified in 5 patients; median survival was 6 months, with 3 long-term survivors.
Conclusions:
- Extensive search for primary lesion is unwarranted in disseminated embryonal malignancies.
- Adequate tumor sampling is crucial for definitive diagnosis.
- Tumor-specific therapy may improve disease control, quality of life, and long-term survival despite low cure rates.